Orthocell Limited (ASX:OCC)

Market Cap	208.33M -40.6%
Revenue (ttm)	11.41M +45.4%
Net Income	-13.91M
EPS	-0.05
Shares Out	272.33M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	308,384
Open	0.7700
Previous Close	0.7650
Day's Range	0.7650 - 0.7900
52-Week Range	0.6700 - 1.6000
Beta	-0.06
Analysts	Strong Buy
Price Target	1.14 (+49.02%)
Est. Earnings	Oct 20, 2026

About Orthocell

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally. It offers Ortho Autologous Chondrocyte Implantation, a cartilage cell therapy for treatment of articular cartilage defects in the knee and ankle; OrthoATI, for treatment of chronic tendon injuries; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental applications; and Remplir, a collagen sc...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: OCC

Financial Performance

In fiscal year 2026, Orthocell's revenue was 11.41 million, an increase of 45.37% compared to the previous year's 7.85 million. Losses were -13.91 million, 62.4% more than in 2025.

Analyst Summary

According to 2 analysts, the average rating for OCC stock is "Strong Buy." The 12-month stock price target is $1.14, which is an increase of 49.02% from the latest price.

Price Target

$1.14

(49.02% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 1, 2026

Data Sources Report a data error